Selected Cancer-Related Publications:
King JC, Lu QY, Li G, Moro A, Takahashi H, Chen M, Go VL, Reber HA, Eibl G, Hines OJ. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochim Biophys Acta. 2012 Feb;1823(2):593-604. Epub 2011 Dec 29
Donahue TR, Isacoff WH, Hines OJ, Tomlinson JS, Farrell JJ, Bhat YM, Garon E, Clerkin B, Reber HA. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch Surg. 2011 Jul;146(7):836-43.
Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M, Go VL, Reber HA, Eibl G, Hines OJ. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol. 2011 Mar;178(3):1340-9.
El Fitori J, Su Y, Buchler P, Ludwig R, Giese NA, Buchler MW, Quentmeier H, Hines OJ, Herr I, Friess H. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. Cancer. 2007 Oct 1;110(7):1457-68.
Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, Eibl G. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007 Aug 1;67(15):7068-71. Epub 2007 Jul 24